- Home
- Products
- Customized ADCs
- IL5
- Anti-IL5 (Reslizumab)-MC-MMAF ADC
Anti-IL5 (Reslizumab)-MC-MMAF ADC (CAT#: ADC-W-1396)
This ADC product is comprised of an anti-IL5 monoclonal antibody conjugated via a MC linker to MMAF. The MMAF is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAF binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Name
- IL5
- Alternative Names
- IL5; interleukin 5 (colony-stimulating factor, eosinophil); interleukin-5; B cell differentiation factor I; EDF; eosinophil differentiation factor; IL 5; interleukin 5; T cell replacing factor; TRF; T-cell replacing factor; B-cell differentiation factor I; IL-5;
- Target Entrez Gene ID
- 3567
- Target UniProt ID
- P05113
- Overview
- This gene encodes a cytokine that acts as a growth and differentiation factor for both B cells and eosinophils. The encoded cytokine plays a major role in the regulation of eosinophil formation, maturation, recruitment and survival. The increased production of this cytokine may be related to pathogenesis of eosinophil-dependent inflammatory diseases. This cytokine functions by binding to its receptor, which is a heterodimer, whose beta subunit is shared with the receptors for interleukine 3 (IL3) and colony stimulating factor 2 (CSF2/GM-CSF). This gene is located on chromosome 5 within a cytokine gene cluster which includes interleukin 4 (IL4), interleukin 13 (IL13), and CSF2 . This gene, IL4, and IL13 may be regulated coordinately by long-range regulatory elements spread over 120 kilobases on chromosome 5q31.
- Overview
- Humanized Anti-IL5 IgG2 antibody, Reslizumab
- Generic name
- Reslizumab
- Host animal
- Rat
- Name
- MC (maleimidocaproyl)
- Description
- Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation.
- Name
- MMAF
- Description
- Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-CD3E (Otelixizumab)-MC-MMAF ADC (CAT#: ADC-W-2476)
- Anti-RTN4 (Ozanezumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-1745)
- Anti-ER-a36-Mc-VC-PABC-MMAE ADC (CAT#: ADC-W-203)
- Anti-TACSTD2-VC-MMAD ADC-2 (CAT#: ADC-W-568)
- Anti-IL5RA (Benralizumab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-1404)
- Anti-DLL3-PBD dimers ADC-3 (CAT#: ADC-W-105)
- Anti-IL6 (Siltuximab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-1428)
- Anti-IL6 (Siltuximab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-1427)
- Anti-TPBG-Mc-MMAD ADC-6 (CAT#: ADC-W-162)
- Anti-C. albicans Hsp90 (Efungumab)-MC-MMAF ADC (CAT#: ADC-W-2194)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-1396. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Linker
Same Payload
| CAT# | Product Name | Linker | Payload |
| ADC-W-1399 | Anti-IL5 (Reslizumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| ADC-W-1388 | Anti-IL5 (Crenezumab)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
| ADC-W-1390 | Anti-IL5 (Crenezumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-1393 | Anti-IL5 (Crenezumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| ADC-W-1397 | Anti-IL5 (Reslizumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| CAT# | Product Name | Linker | Payload |
| ADC-W-114 | Anti-CD33-Mc-MMAF ADC-3 | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| ADC-W-485 | Anti-EphA2-Mc-MMAF ADC-1 | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| ADC-W-452 | Anti-CD70-Mc-MMAF ADC-1 | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| ADC-W-491 | Anti-TNFRSF17-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| ADC-W-115 | Anti-CD33-Mc-MMAF ADC-1 | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| CAT# | Product Name | Linker | Payload |
| ADC-W-2622 | Anti-NCAM1 (Lorvotuzumab )-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2573 | Anti-SLC34A2 (Lifastuzumab )-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2591 | Anti-EGFR (Cetuximab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-AA-064 | Anti-HIgG(Fab)-C-MMAF ADC | Cleavable linkers | MMAF |
| ADC-AA-063 | Anti-HIgG(Fab)-N-MMAF ADC | Noncleavable linkers | MMAF |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
